文献速递类风湿关节炎

循环CD19+CD24hiCD38hi调节性B细胞可作为早期类风湿关节炎甲氨蝶呤应答的生物标志物

Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究纳入48例未用激素及DMARD、病程<24周的早期RA患者和48例健康对照,用流式细胞术检测循环CD19+CD24hiCD38hi过渡型(cTr)B细胞频率。早期RA患者cTr B细胞频率升高,基线cTr B细胞频率高于健康对照中位值者12个月时EULAR良好应答相对风险为2.91(95%CI 1.37, 6.47),且甲氨蝶呤启动12个月后cTr B细胞频率显著下降。

要点

  • 早期RA患者循环cTr B细胞频率较健康对照升高。
  • 基线cTr B细胞高于健康对照中位值与MTX 12个月良好EULAR应答相关,RR 2.91(95%CI 1.37, 6.47)。
  • 启动MTX 12个月后cTr B细胞频率显著下降,不依赖临床应答程度或泼尼松使用。

核心结论

  • 未治疗的早期RA中调节性cTr B细胞频率升高,基线cTr B细胞频率与12个月时MTX临床应答相关。

研究设计与样本

  • 研究纳入48例未用激素及DMARD、病程<24周的早期RA患者和48例健康对照,采用流式细胞术检测新鲜外周血单个核细胞。
  • 研究建立分离记忆B细胞与自体T细胞的共培养,并比较有无Tr B细胞存在时的培养结果。

主要发现

  • 与健康对照相比,早期RA患者cTr B细胞频率升高。
  • 早期RA患者与健康对照的cTr B细胞均显示抗炎细胞因子谱,并能下调自体B/T细胞共培养中T细胞IFN-γ和IL-21产生及ACPA分泌。
  • 基线cTr B细胞频率高于健康对照中位值与12个月时MTX良好EULAR应答相关,相对风险2.91(95%CI 1.37, 6.47)。
  • 启动MTX 12个月后cTr B细胞频率显著下降,不再升高而呈降低,且不依赖临床应答程度或泼尼松摄入。

关键数值与推荐

  • 基线cTr B细胞频率高于健康对照中位值者,12个月时MTX良好EULAR应答的相对风险为2.91(95%CI 1.37, 6.47)。

临床怎么用

  • 基线cTr B细胞频率或可作为早期RA患者启动MTX后12个月临床应答的预测标志物。
  • 早期RA患者cTr B细胞频率在MTX治疗12个月后下降,解读该指标时需考虑治疗时间点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The protagonism of regulatory B cells seems to vary along the course of the disease in murine models of inflammatory conditions. Decreased numbers of circulating regulatory CD19+CD24hiCD38hi transitional (cTr) B cells have been described in patients with long-standing RA, thus our objective was to examine the frequency and evolution of cTr B cells in the peripheral blood of early RA (ERA) patients. METHODS: Freshly isolated peripheral blood mononuclear cells from 48 steroid- and DMARD-naïve ERA patients with a disease duration of <24 weeks and 48 healthy controls (HCs) were examined by flow cytometry. Co-cultures of isolated memory B cells were established with autologous T cells in the absence or presence of Tr B cells. RESULTS: As compared with HCs, ERA patients demonstrated an increased frequency of cTr B cells. cTr B cells of ERA patients and HCs displayed an anti-inflammatory cytokine profile and were able to downregulate T cell IFN-γ and IL-21 production, together with ACPA secretion in autologous B/T cell co-cultures. Basal frequencies of cTr B cells above the median value observed in HCs were associated with a good EULAR response to MTX at 12 months [relative risk 2.91 (95% CI 1.37, 6.47)]. A significant reduction of cTr B cells was observed 12 months after initiating MTX, when the cTr B cell frequency was no longer elevated but decreased, and this was independent of the degree of clinical response or the intake of prednisone. CONCLUSION: An increased frequency of regulatory cTr B cells is apparent in untreated ERA and the baseline cTr B cell frequency is associated with the clinical response to MTX at 12 months.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fortea-Gordo P, Villalba A, Nuño L, et al. Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 32417912. doi:10.1093/rheumatology/keaa186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。